Group 1 - The pharmaceutical and biotechnology industry is expected to experience a valuation recovery driven by the recent chikungunya fever outbreak and its innovative attributes [1] - The diagnostic sector has already absorbed the previous COVID-19 base, and the pandemic may create new demand [1] - The pharmacy sector is exploring new business models to improve profitability in response to the impact of medical insurance reforms, with potential performance improvements in H2 2025 triggering valuation recovery [1] Group 2 - The long-term focus for the industry is on "innovation + AI healthcare + recovery," with the medical insurance bureau clearly supporting differentiated innovation [1] - The WAIC conference is expected to catalyze opportunities in AI healthcare, while the recovery in medical device procurement and global biotech financing will boost demand for CXO and upstream life sciences [1] - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in the research, production, and sales of innovative drugs to reflect the overall performance of high-growth and technologically advanced firms in the pharmaceutical and biotechnology sector [1]